ArticleInternational journal of oncology2022

The TLR7/8 agonist R848 optimizes host and tumor immunity to improve therapeutic efficacy in murine lung cancer.

Jianchun Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.